{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:35:54Z","timestamp":1786116954628,"version":"build-2736575974"},"reference-count":137,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neuroimmunological overlap syndromes encompassing optic neuritis, myelitis, and connective tissue disorders (CTDs) represent an emerging autoimmune spectrum at the intersection of neurology, immunology, and rheumatology. These conditions share convergent pathogenic mechanisms including blood\u2013brain barrier dysfunction, cytokine dysregulation, complement activation, and adaptive immune imbalance, yet are often managed as discrete entities despite overlapping clinical features.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>A narrative review was conducted across PubMed, Web of Science, and Google Scholar (January 2014\u2013March 2026) using keywords related to NMOSD, MOGAD, MS, optic neuritis, myelitis, and CTDs. Preference was given to systematic reviews, meta-analyses, randomized controlled trials, and large observational cohort studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes<\/jats:title>\n                    <jats:p>\n                      Shared pathogenic mechanisms include BBB disruption, pro-inflammatory cytokines (IL-6, IL-17, TNF-\n                      <jats:italic>\u03b1<\/jats:italic>\n                      , IFN-\n                      <jats:italic>\u03b3<\/jats:italic>\n                      ), complement activation, and B-cell\/Th17-mediated autoimmunity. Disease-defining antibodies (AQP4-IgG, MOG-IgG) have refined diagnostic accuracy. Clinically, optic neuritis and myelitis serve as principal overlapping manifestations complicating differentiation among NMOSD, MOGAD, MS, and CTD-associated neuroinflammation. Four biologics inebilizumab (B-cell depletion), satralizumab (IL-6 blockade), and eculizumab\/ravulizumab (complement inhibition) are approved for AQP4-IgG-positive NMOSD. However, no targeted therapies exist for MOGAD, and CTD-associated neuroinflammation lacks trial data. Emerging biomarkers (GFAP, NfL) and precision medicine tools remain unvalidated for routine clinical use.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Neuroimmunological overlap syndromes should be conceptualized as a unified neuroimmune continuum rather than discrete diseases. Priority research includes biomarker validation, head-to-head comparative cohorts, and randomized trials for MOGAD and CTD-associated neuroinflammation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2026.1887536","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:54:12Z","timestamp":1784699652000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Neuroimmunological overlap syndromes in optic neuritis, myelitis, and connective tissue diseases"],"prefix":"10.3389","volume":"17","author":[{"given":"Shu-ting","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Neurology, Huizhou Central People\u2019s Hospital","place":["Huizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-wen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Huizhou Central People\u2019s Hospital","place":["Huizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"5781","DOI":"10.1113\/JP271539","article-title":"Anti-inflammatory properties of the vagus nerve: potential therapeutic implications of vagus nerve stimulation","volume":"594","author":"Bonaz","year":"2016","journal-title":"J Physiol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1172\/JCI124609","article-title":"Neuro-immune crosstalk and allergic inflammation","volume":"129","author":"Kabata","year":"2019","journal-title":"J Clin Invest"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/978-94-017-7537-3_6","article-title":"Peripheral nociceptors as immune sensors in the development of pain and itch","volume":"904","author":"Wang","year":"2016","journal-title":"Adv Exp Med Biol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.it.2006.11.007","article-title":"What is the blood-brain barrier (not)?","volume":"28","author":"Bechmann","year":"2007","journal-title":"Trends Immunol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.brainresbull.2019.09.003","article-title":"Neuroimmune crosstalk in central nervous system injury-induced infection and pharmacological intervention","volume":"153","author":"Huang","year":"2019","journal-title":"Brain Res Bull"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/rheumatology\/kex528","article-title":"The relationship between depression and biologic treatment response in rheumatoid arthritis: an analysis of the British Society for Rheumatology biologics register","volume":"57","author":"Matcham","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"721","DOI":"10.2165\/11591670-000000000-00000","article-title":"Neuropsychiatric manifestations in systemic lupus erythematosus: epidemiology, pathophysiology and management","volume":"25","author":"Postal","year":"2011","journal-title":"CNS Drugs"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jpsychores.2009.05.011","article-title":"The association between arthritis and psychiatric disorders; results from a longitudinal population-based study","volume":"68","author":"van 't Land","year":"2010","journal-title":"J Psychosom Res"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"103465","DOI":"10.1016\/j.autrev.2023.103465","article-title":"A comprehensive review of the advances in neuromyelitis optica spectrum disorder","volume":"22","author":"Siriratnam","year":"2023","journal-title":"Autoimmun Rev"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.berh.2019.02.003","article-title":"Central nervous system involvement in rheumatoid arthritis patients and the potential implications of using biological agents","volume":"32","author":"Atzeni","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"612104","DOI":"10.3389\/fimmu.2020.612104","article-title":"The joint-brain Axis: insights from rheumatoid arthritis on the crosstalk between chronic peripheral inflammation and the brain","volume":"11","author":"S\u00fc\u00df","year":"2020","journal-title":"Front Immunol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/741490","article-title":"Immunotherapy of neuromyelitis optica","volume":"2013","author":"Bienia","year":"2013","journal-title":"Autoimmune Dis"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"102921","DOI":"10.1016\/j.arr.2025.102921","article-title":"From pathogenesis to precision medicine: targeting immune imbalance in multiple sclerosis","volume":"113","author":"Pithakumar","year":"2026","journal-title":"Ageing Res Rev"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e70712","DOI":"10.1002\/mco2.70712","article-title":"Blood\u2013brain barrier: structure, function, diseases, and drug delivery systems","volume":"7","author":"He","year":"2026","journal-title":"MedComm"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"117177","DOI":"10.1016\/j.biopha.2024.117177","article-title":"The interplay between cytokines, inflammation, and antioxidants: mechanistic insights and therapeutic potentials of various antioxidants and anti-cytokine compounds","volume":"178","author":"Bhol","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms251910625","article-title":"Blood-brain barrier disruption in neuroimmunological disease","volume":"25","author":"Shimizu","year":"2024","journal-title":"Int J Mol Sci"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"101177","DOI":"10.1016\/j.bbih.2026.101177","article-title":"AQP4-IgG and mood disorders: case series of neuromyelitis optica spectrum disorder","volume":"52","author":"Xu","year":"2026","journal-title":"Brain Behav Immun Health"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s13577-026-01381-5","article-title":"Pathogenesis and therapeutic strategies for neuropsychiatric lupus centered on innate immune activation","volume":"39","author":"Nagata","year":"2026","journal-title":"Hum Cell"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/ph18010104","article-title":"Targeting cytokine-mediated inflammation in brain disorders: developing new treatment strategies","volume":"18","author":"Mallick","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000841","article-title":"Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology","volume":"7","author":"Fujihara","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26062505","article-title":"The role of IL-17A in mediating inflammatory responses and progression of neurodegenerative diseases","volume":"26","author":"Zheng","year":"2025","journal-title":"Int J Mol Sci"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/cells14181408","article-title":"White matter in crisis: oligodendrocytes and the pathophysiology of multiple sclerosis","volume":"14","author":"Garc\u00eda-Dom\u00ednguez","year":"2025","journal-title":"Cells"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1002\/mco2.147","article-title":"Role of chemokine systems in cancer and inflammatory diseases","volume":"3","author":"Li","year":"2020","journal-title":"MedComm"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s40744-021-00312-0","article-title":"Cognitive dysfunction in systemic lupus erythematosus: immunopathology, clinical manifestations, neuroimaging and management","volume":"8","author":"Seet","year":"2021","journal-title":"Rheumatol Ther"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/nyas.12794","article-title":"Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later","volume":"1366","author":"Pittock","year":"2016","journal-title":"Ann N Y Acad Sci"},{"key":"ref27","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.1071519","article-title":"Neuromyelitis optica spectrum disorders associated with AQP4-positive-cancer\u2014a case series","volume":"13","author":"Duan","year":"2022","journal-title":"Front Neurol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26178538","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease: pathophysiology, clinical patterns, and therapeutic challenges of intractable and severe forms","volume":"26","author":"Misu","year":"2025","journal-title":"Int J Mol Sci"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3389\/fimmu.2018.00541","article-title":"Autoantibodies associated with connective tissue diseases: what meaning for clinicians?","volume":"9","author":"Didier","year":"2018","journal-title":"Front Immunol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3390\/ijms262311736","article-title":"Autoimmune neuromuscular disorders at a molecular crossroad: linking pathogenesis to targeted immunotherapy","volume":"26","author":"Florea","year":"2025","journal-title":"Int J Mol Sci"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12974-022-02605-9","article-title":"The role of the adaptive immune system and T cell dysfunction in neurodegenerative diseases","volume":"19","author":"DeMaio","year":"2022","journal-title":"J Neuroinflammation"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s00281-009-0186-z","article-title":"Th17 cells in autoimmune demyelinating disease","volume":"32","author":"Segal","year":"2010","journal-title":"Semin Immunopathol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/j.1749-6632.2009.05133.x","article-title":"Th1 and Th17 cells: adversaries and collaborators","volume":"1183","author":"Damsker","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s40259-025-00729-x","article-title":"Emerging role of targeted monoclonal antibodies in Neuromyelitis Optica Spectrum disorders","volume":"39","author":"Holian","year":"2025","journal-title":"BioDrugs"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s40263-022-00949-7","article-title":"Inebilizumab: a review in Neuromyelitis Optica Spectrum disorder","volume":"36","author":"Nie","year":"2022","journal-title":"CNS Drugs"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1007\/s00415-021-10744-x","article-title":"Anti-CD20 therapies for multiple sclerosis: current status and future perspectives","volume":"269","author":"Margoni","year":"2022","journal-title":"J Neurol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/WCO.0000000000000694","article-title":"Neuromyelitis optica spectrum disorders: still evolving and broadening","volume":"32","author":"Fujihara","year":"2019","journal-title":"Curr Opin Neurol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"e14973","DOI":"10.1111\/1756-185X.14973","article-title":"Neuromyelitis optica spectrum disorders (NMOSD) and systemic lupus erythematosus (SLE): dangerous duo","volume":"27","author":"Abou Raya","year":"2024","journal-title":"Int J Rheum Dis"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"372","DOI":"10.31138\/mjr.20230808.tc","article-title":"The coexisting Neuromyelitis Optica Spectrum disorder and systemic lupus erythematosus: a therapeutic challenge","volume":"34","author":"Kumar","year":"2023","journal-title":"Mediterr J Rheumatol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1559172","DOI":"10.3389\/fneur.2025.1559172","article-title":"Advances in biomarkers for optic neuritis and neuromyelitis optica spectrum disorders: a multi-omics perspective","volume":"16","author":"Liu","year":"2025","journal-title":"Front Neurol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1634127","DOI":"10.3389\/fneur.2025.1634127","article-title":"Clinical features and prognosis of NMOSD patients with positive autoimmune antibodies","volume":"16","author":"Liu","year":"2025","journal-title":"Front Neurol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12883-018-1182-5","article-title":"Neuromyelitis optica spectrum disorders with and without connective tissue disorders","volume":"18","author":"Yang","year":"2018","journal-title":"BMC Neurol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.3390\/biom12040591","article-title":"Aquaporin-4 in Neuromyelitis Optica Spectrum disorders: a target of autoimmunity in the central nervous system","volume":"12","author":"Abe","year":"2022","journal-title":"Biomolecules"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.preteyeres.2013.03.001","article-title":"Optic neuritis in neuromyelitis optica","volume":"36","author":"Levin","year":"2013","journal-title":"Prog Retin Eye Res"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1007\/s00415-023-11634-0","article-title":"Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) \u2013 revised recommendations of the Neuromyelitis Optica study group (NEMOS). Part I: diagnosis and differential diagnosis","volume":"270","author":"Jarius","year":"2023","journal-title":"J Neurol"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1055\/s-0042-1743211","article-title":"Longitudinally extensive transverse myelitis: one disease, variable outcomes-a case series","volume":"13","author":"Chandrasekar","year":"2022","journal-title":"J Neurosci Rural Pract"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: international MOGAD panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.autrev.2015.12.004","article-title":"Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination","volume":"15","author":"Ramanathan","year":"2016","journal-title":"Autoimmun Rev"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41582-018-0112-x","article-title":"Myelin oligodendrocyte glycoprotein antibodies in neurological disease","volume":"15","author":"Reindl","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"e1858","DOI":"10.1212\/WNL.0000000000005560","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: the MOGADOR study","volume":"90","author":"Cobo-Calvo","year":"2018","journal-title":"Neurology"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"83","DOI":"10.5935\/0004-2749.20230012","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated optic neuritis: an update","volume":"86","author":"Messias","year":"2023","journal-title":"Arq Bras Oftalmol"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/s41433-020-01334-8","article-title":"Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disorder-optic neuritis: a comprehensive review of diagnosis and treatment","volume":"35","author":"Gospe","year":"2021","journal-title":"Eye (Lond)"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"e0170847","DOI":"10.1371\/journal.pone.0170847","article-title":"Retinal nerve Fiber layer may be better preserved in MOG-IgG versus AQP4-IgG optic neuritis: a cohort study","volume":"12","author":"Stiebel-Kalish","year":"2017","journal-title":"PLoS One"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1001\/jamaneurol.2018.4053","article-title":"Clinical, radiologic, and prognostic features of myelitis associated with myelin oligodendrocyte glycoprotein autoantibody","volume":"76","author":"Dubey","year":"2019","journal-title":"JAMA Neurol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1011579","DOI":"10.3389\/fneur.2022.1011579","article-title":"Myelitis features and outcomes in CNS demyelinating disorders: comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD","volume":"13","author":"Fadda","year":"2022","journal-title":"Front Neurol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","article-title":"Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"75","author":"Hacohen","year":"2018","journal-title":"JAMA Neurol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1177\/1352458519893093","article-title":"MRI differences between MOG antibody disease and AQP4 NMOSD","volume":"26","author":"Salama","year":"2020","journal-title":"Mult Scler"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"885218","DOI":"10.3389\/fneur.2022.885218","article-title":"Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): a review of clinical and MRI features, diagnosis, and management","volume":"13","author":"Sechi","year":"2022","journal-title":"Front Neurol"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.neurol.2020.06.016","article-title":"MRI characteristics of MOG-ab associated disease in adults: an update","volume":"177","author":"Shor","year":"2021","journal-title":"Rev Neurol (Paris)"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1177\/1352458515591071","article-title":"Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: clinical and prognostic implications","volume":"22","author":"Cobo-Calvo","year":"2016","journal-title":"Mult Scler"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12974-016-0717-1","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflammation"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1001\/jamaneurol.2019.2940","article-title":"Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes","volume":"77","author":"Waters","year":"2020","journal-title":"JAMA Neurol"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","article-title":"Myelin-oligodendrocyte glycoprotein antibody-associated disease","volume":"20","author":"Marignier","year":"2021","journal-title":"Lancet Neurol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"105941","DOI":"10.1016\/j.msard.2024.105941","article-title":"New insights into the use of high dose corticosteroids and plasmapheresis in persons with MOGAD and NMOSD","volume":"92","author":"Kosior","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"106602","DOI":"10.1016\/j.msard.2025.106602","article-title":"Treatment strategies of AQP4-IgG positive neuromyelitis optica spectrum disorder and MOG antibody-associated disorder in Switzerland: a nationwide survey","volume":"102","author":"Steinegger","year":"2025","journal-title":"Mult Scler Relat Disord"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1177\/13524585231184738","article-title":"Intravenous immunoglobulin treatment for acute attacks in myelin oligodendrocyte glycoprotein antibody disease","volume":"29","author":"Lotan","year":"2023","journal-title":"Mult Scler"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"e213903","DOI":"10.1212\/WNL.0000000000213903","article-title":"Outcomes after acute plasma exchange for myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"105","author":"Thakolwiboon","year":"2025","journal-title":"Neurology"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12974-019-1525-1","article-title":"Evaluation of treatment response in adults with relapsing MOG-ab-associated disease","volume":"16","author":"Cobo-Calvo","year":"2019","journal-title":"J Neuroinflammation"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1007\/s00415-020-10026-y","article-title":"Treatment of MOG antibody associated disorders: results of an international survey","volume":"267","author":"Whittam","year":"2020","journal-title":"J Neurol"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/jamaneurol.2022.0489","article-title":"Association of maintenance intravenous immunoglobulin with prevention of relapse in adult myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"79","author":"Chen","year":"2022","journal-title":"JAMA Neurol"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in Aquaporin-4-positive Neuromyelitis Optica Spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/B978-0-323-90887-0.00015-8","article-title":"Immunotherapies for neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"214","author":"Lotan","year":"2026","journal-title":"Handb Clin Neurol"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/s41392-025-02415-4","article-title":"Multiple sclerosis: molecular pathogenesis and therapeutic intervention","volume":"10","author":"Boutitah-Benyaich","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci7100138","article-title":"Pattern recognition of the multiple sclerosis syndrome","volume":"7","author":"Zabad","year":"2017","journal-title":"Brain Sci"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"102975","DOI":"10.1016\/j.msard.2021.102975","article-title":"Multiple sclerosis-like NMOSD patients suffer severe worsening of status after fingolimod initiation","volume":"52","author":"Bonnan","year":"2021","journal-title":"Mult Scler Relat Disord"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"e00588","DOI":"10.1016\/j.neurot.2025.e00588","article-title":"Role of soluble biomarkers in treating multiple sclerosis and neuroinflammatory conditions","volume":"22","author":"Bose","year":"2025","journal-title":"Neurotherapeutics"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"969762","DOI":"10.3389\/fneur.2022.969762","article-title":"Comparative analysis of clinical and imaging data of first-attack neuromyelitis optica spectrum disorders with and without connective tissue disease","volume":"13","author":"Yao","year":"2022","journal-title":"Front Neurol"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29040747","article-title":"Neuropsychiatric systemic lupus erythematosus: molecules involved in its imunopathogenesis, clinical features, and treatment","volume":"29","author":"Justiz-Vaillant","year":"2024","journal-title":"Molecules"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"998328","DOI":"10.3389\/fcell.2022.998328","article-title":"Pathogenesis and treatment of neuropsychiatric systemic lupus erythematosus: a review","volume":"10","author":"Liu","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"e4806","DOI":"10.7759\/cureus.4806","article-title":"Systemic lupus erythematosus presenting as optic neuropathy: a case report","volume":"11","author":"Zahid","year":"2019","journal-title":"Cureus"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"e80092","DOI":"10.7759\/cureus.80092","article-title":"Spectrum of neurological complications in Sj\u00f6gren's syndrome: a comprehensive review","volume":"17","author":"Fahad","year":"2025","journal-title":"Cureus"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13075-025-03538-3","article-title":"Concomitant Sj\u00f6gren's disease in patients with NMOSD: impacts on neurologic disease severity and recurrence","volume":"27","author":"Wu","year":"2025","journal-title":"Arthritis Res Ther"},{"key":"ref84","doi-asserted-by":"crossref","first-page":"284","DOI":"10.31138\/mjr.20230801.oo","article-title":"Overview of rheumatoid arthritis and scientific understanding of the disease","volume":"34","author":"Jahid","year":"2023","journal-title":"Mediterr J Rheumatol"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.rdc.2017.06.005","article-title":"Neurologic manifestations of rheumatoid arthritis","volume":"43","author":"DeQuattro","year":"2017","journal-title":"Rheum Dis Clin N Am"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/cns.13569","article-title":"Peripheral inflammation and blood-brain barrier disruption: effects and mechanisms","volume":"27","author":"Huang","year":"2021","journal-title":"CNS Neurosci Ther"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"e70079","DOI":"10.1111\/cns.70079","article-title":"Endothelial dysfunctions in blood\u2013brain barrier breakdown in Alzheimer's disease: from mechanisms to potential therapies","volume":"30","author":"Yue","year":"2024","journal-title":"CNS Neurosci Ther"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/acr.23539","article-title":"Increased burden of psychiatric disorders in rheumatoid arthritis","volume":"70","author":"Marrie","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/nrrheum.2016.112","article-title":"Affective disturbance in rheumatoid arthritis: psychological and disease-related pathways","volume":"12","author":"Sturgeon","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s41927-019-0092-5","article-title":"The multifaceted impact of anxiety and depression on patients with rheumatoid arthritis","volume":"3","author":"Peterson","year":"2019","journal-title":"BMC Rheumatol"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"991","DOI":"10.2147\/IMCRJ.S493262","article-title":"Thyroid-associated optic neuropathy: a case report of optic neuritis due to autoimmune hypothyroidism","volume":"17","author":"Hidig","year":"2024","journal-title":"Int Med Case Rep J"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"1383255","DOI":"10.3389\/fimmu.2024.1383255","article-title":"Autoimmune encephalitis followed by hemophagocytic lymph histiocytosis: a case report","volume":"15","author":"Huang","year":"2024","journal-title":"Front Immunol"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1212\/con.0000000000000768","article-title":"Optic neuritis","volume":"25","author":"Bennett","year":"2019","journal-title":"Continuum (Minneap Minn)"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"169","DOI":"10.7861\/clinmedicine.19-2-169","article-title":"Neuromyelitis optica spectrum disorders","volume":"19","author":"Huda","year":"2019","journal-title":"Clin Med (Lond)"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"e13968","DOI":"10.7759\/cureus.13968","article-title":"Longitudinally extensive transverse myelitis: a retrospective study differentiating neuromyelitis optica spectrum disorder from other etiologies","volume":"13","author":"Paudel","year":"2021","journal-title":"Cureus"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"735486","DOI":"10.1155\/2012\/735486","article-title":"Brain abnormalities in neuromyelitis optica spectrum disorder","volume":"2012","author":"Kim","year":"2012","journal-title":"Mult Scler Int"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"646940","DOI":"10.3389\/fimmu.2021.646940","article-title":"Longitudinal CSF findings in autoimmune encephalitis-a monocentric cohort study","volume":"12","author":"Zrzavy","year":"2021","journal-title":"Front Immunol"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11020425","article-title":"Cerebrospinal fluid biomarkers in differential diagnosis of multiple sclerosis and systemic inflammatory diseases with central nervous system involvement","volume":"11","author":"\u015awiderek-Matysiak","year":"2023","journal-title":"Biomedicine"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.4103\/NRR.NRR-D-24-00109","article-title":"Biomarkers for neuromyelitis optica: a visual analysis of emerging research trends","volume":"19","author":"Li","year":"2024","journal-title":"Neural Regen Res"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"746959","DOI":"10.3389\/fneur.2021.746959","article-title":"Serum aquaporin 4-immunoglobulin G titer and Neuromyelitis Optica Spectrum disorder activity and severity: a systematic review and Meta-analysis","volume":"12","author":"Liu","year":"2021","journal-title":"Front Neurol"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"635419","DOI":"10.3389\/fneur.2021.635419","article-title":"Anti-aquaporin 4 IgG is not associated with any clinical disease characteristics in Neuromyelitis Optica Spectrum disorder","volume":"12","author":"Schmetzer","year":"2021","journal-title":"Front Neurol"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1093\/brain\/awaa347","article-title":"Quantitative spinal cord MRI in MOG-antibody disease, neuromyelitis optica and multiple sclerosis","volume":"144","author":"Mariano","year":"2021","journal-title":"Brain"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"865730","DOI":"10.3389\/fneur.2022.865730","article-title":"Glial fibrillary acidic protein in blood as a disease biomarker of Neuromyelitis Optica Spectrum disorders","volume":"13","author":"Kim","year":"2022","journal-title":"Front Neurol"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1177\/13524585221097296","article-title":"Serum neurofilament light chain concentration predicts disease worsening in multiple sclerosis","volume":"28","author":"Brune","year":"2022","journal-title":"Mult Scler"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"1322125","DOI":"10.3389\/fimmu.2024.1322125","article-title":"Single-cell RNA sequencing reveals cell type-specific immune regulation associated with human neuromyelitis optica spectrum disorder","volume":"15","author":"Jiang","year":"2024","journal-title":"Front Immunol"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1186\/s12967-025-06996-0","article-title":"Droplet-based single-cell RNA sequencing: decoding cellular heterogeneity for breakthroughs in cancer, reproduction, and beyond","volume":"23","author":"Luo","year":"2025","journal-title":"J Transl Med"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12916-024-03418-8","article-title":"Peripheral GFAP and NfL as early biomarkers for dementia: longitudinal insights from the UK biobank","volume":"22","author":"Wang","year":"2024","journal-title":"BMC Med"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"1665688","DOI":"10.3389\/fimmu.2025.1665688","article-title":"Decoding paraneoplastic neuromyelitis optica: a multi-omics investigation of tumor-driven T and B cell dynamics","volume":"16","author":"Huang","year":"2025","journal-title":"Front Immunol"},{"key":"ref109","doi-asserted-by":"crossref","first-page":"11375","DOI":"10.2147\/JIR.S474211","article-title":"Single-cell transcriptome reveals the heterogeneity of T cells in mice with systemic lupus erythematosus and neuronal inflammation","volume":"17","author":"Shi","year":"2024","journal-title":"J Inflamm Res"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/eji.202149757","article-title":"Multiple sclerosis: Immunopathological heterogeneity and its implications","volume":"52","author":"Engelhardt","year":"2022","journal-title":"Eur J Immunol"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"e0318824","DOI":"10.1371\/journal.pone.0318824","article-title":"HLA-class II genes association with multiple sclerosis: an immunogenetic prediction among multiple sclerosis Jordanian patients","volume":"20","author":"Khdair","year":"2025","journal-title":"PLoS One"},{"key":"ref112","article-title":"Protective allele for multiple sclerosis HLA-DRB1*01:01 provides kinetic discrimination of myelin and exogenous antigenic peptides [original research]","volume":"10","author":"Mamedov","year":"2019","journal-title":"Front Immunol"},{"key":"ref113","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/NRL.0000000000000394","article-title":"Association analysis between HLA-DQA1 loci and Neuromyelitis Optica Spectrum disorder in a Han Chinese population","volume":"27","author":"Zhou","year":"2022","journal-title":"Neurologist"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22062801","article-title":"Neuromyelitis Optica Spectrum disorder treatment-current and future prospects","volume":"22","author":"Waliszewska-Pros\u00f3\u0142","year":"2021","journal-title":"Int J Mol Sci"},{"key":"ref115","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2147\/ITT.S40675","article-title":"Current and emerging treatment options in the management of lupus","volume":"5","author":"Jordan","year":"2016","journal-title":"Immunotargets Ther"},{"key":"ref116","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11940-015-0387-9","article-title":"Treatment of Neuromyelitis Optica Spectrum disorder: acute, preventive, and symptomatic","volume":"18","author":"Kessler","year":"2016","journal-title":"Curr Treat Options Neurol"},{"key":"ref117","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1586\/1744666X.2015.1082908","article-title":"Treatment of inflammatory myopathy: emerging therapies and therapeutic targets","volume":"11","author":"Moghadam-Kia","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11123180","article-title":"Plasma exchange versus intravenous immunoglobulin in worsening myasthenia gravis: a systematic review and Meta-analysis with special attention to faster relapse control","volume":"11","author":"Pavlekovics","year":"2023","journal-title":"Biomedicine"},{"key":"ref119","doi-asserted-by":"publisher","first-page":"e68895","DOI":"10.7759\/cureus.68895","article-title":"Comparative analysis of intravenous immunoglobulins (IVIg) vs plasmapheresis (PLEX) in the Management of Myasthenic Crisis","volume":"16","author":"Zain","year":"2024","journal-title":"Cureus"},{"key":"ref120","doi-asserted-by":"publisher","first-page":"e70628","DOI":"10.1111\/cns.70628","article-title":"Lymphoplasmapheresis for steroid-refractory Neuromyelitis Optica Spectrum disorder: a real-world multicenter study in China","volume":"31","author":"Zeng","year":"2025","journal-title":"CNS Neurosci Ther"},{"key":"ref121","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s40265-020-01370-4","article-title":"E. Inebilizumab: First Approval","volume":"80","author":"Frampton","year":"2020","journal-title":"Drugs"},{"key":"ref122","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of Satralizumab in Neuromyelitis Optica Spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N Engl J Med"},{"key":"ref123","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1002\/ana.26626","article-title":"Ravulizumab in Aquaporin-4-positive Neuromyelitis Optica Spectrum disorder","volume":"93","author":"Pittock","year":"2023","journal-title":"Ann Neurol"},{"key":"ref124","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1080\/14712598.2021.1884223","article-title":"Targeting the complement system in neuromyelitis optica spectrum disorder","volume":"21","author":"Asavapanumas","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"ref125","doi-asserted-by":"publisher","first-page":"220","DOI":"10.2174\/18756190MTA2cMjAm1","article-title":"Anti-IL-6 therapies for Neuromyelitis Optica Spectrum disorders: a systematic review of safety and efficacy","volume":"19","author":"Lotan","year":"2021","journal-title":"Curr Neuropharmacol"},{"key":"ref126","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1358\/dot.2021.57.3.3251715","article-title":"Satralizumab: an interleukin-6 (IL-6) receptor antagonist for the treatment of neuromyelitis optica spectrum disorders","volume":"57","author":"Paton","year":"2021","journal-title":"Drugs Today (Barc)"},{"key":"ref127","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12974-023-02838-2","article-title":"Caudal DMN neurons innervate the spleen and release CART peptide to regulate neuroimmune function","volume":"20","author":"Kobori","year":"2023","journal-title":"J Neuroinflammation"},{"key":"ref128","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41586-020-2235-7","article-title":"Brain control of humoral immune responses amenable to behavioural modulation","volume":"581","author":"Zhang","year":"2020","journal-title":"Nature"},{"key":"ref129","doi-asserted-by":"publisher","first-page":"1490300","DOI":"10.3389\/fnins.2024.1490300","article-title":"Non-invasive vagus nerve stimulation in anti-inflammatory therapy: mechanistic insights and future perspectives","volume":"18","author":"Liu","year":"2024","journal-title":"Front Neurosci"},{"key":"ref130","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41581-023-00791-0","article-title":"Translating B cell immunology to the treatment of antibody-mediated allograft rejection","volume":"20","author":"Heeger","year":"2024","journal-title":"Nat Rev Nephrol"},{"key":"ref131","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s12974-024-03262-w","article-title":"MOG-specific CAR Tregs: a novel approach to treat multiple sclerosis","volume":"21","author":"Frikeche","year":"2024","journal-title":"J Neuroinflammation"},{"key":"ref132","doi-asserted-by":"publisher","DOI":"10.3390\/cells14141085","article-title":"Inverse vaccination for autoimmune diseases: insights into the role of B lymphocytes","volume":"14","author":"Zouali","year":"2025","journal-title":"Cells"},{"key":"ref133","doi-asserted-by":"publisher","first-page":"1718736","DOI":"10.3389\/fneur.2026.1718736","article-title":"Differential diagnosis between NMOSD and MS: a retrospective study based on clinical and imaging features","volume":"17","author":"Ma","year":"2026","journal-title":"Front Neurol"},{"key":"ref134","doi-asserted-by":"publisher","first-page":"2","DOI":"10.4103\/sjopt.sjopt_102_23","article-title":"Monoclonal antibody therapies for aquaporin-4-immunoglobulin G-positive neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"38","author":"Tisavipat","year":"2024","journal-title":"Saudi J Ophthalmol"},{"key":"ref135","first-page":"26","article-title":"Deep learning and the retina: a new frontier in multiple sclerosis diagnosis","volume":"51","author":"Abdul-Salam","year":"2025","journal-title":"Curr Health Sci J"},{"key":"ref136","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci14121266","article-title":"Artificial intelligence-based methodologies for early diagnostic precision and personalized therapeutic strategies in neuro-ophthalmic and neurodegenerative pathologies","volume":"14","author":"Kumar","year":"2024","journal-title":"Brain Sci"},{"key":"ref137","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12245-025-00870-y","article-title":"AI-assisted ophthalmic imaging for early detection of neurodegenerative diseases","volume":"18","author":"Tukur","year":"2025","journal-title":"Int J Emerg Med"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1887536\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T13:03:46Z","timestamp":1786021426000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2026.1887536\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":137,"alternative-id":["10.3389\/fneur.2026.1887536"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2026.1887536","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"1887536"}}